# Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

> **NCT04826198** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 13 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** AsiDNA
- **DRUG:** Niraparib
- **DRUG:** Olaparib
- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT04826198
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-05
- **Primary completion:** 2024-04-04
- **Final completion:** 2024-04-04
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an improved version, and the contract ensuring access to this molecule has expired.
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826198, "Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04826198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*